Navigation Links
Monitoring blood flow helps improve prostate biopsies, Jefferson researchers report
Date:5/23/2008

(PHILADELPHIA) Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies, according to a new study by urologists and radiologists at the Jefferson Prostate Diagnostic Center and the Kimmel Cancer Center at Jefferson in Philadelphia. The researchers found that biopsies targeted to areas of increased blood flow in the prostate were twice as likely to be positive for cancer compared with conventional prostate biopsy techniques. They reported their initial results from a clinical trial this week at the annual meeting of the American Urological Association in Orlando.

According to Prostate Diagnostic Center co-director Edouard Trabulsi, M.D., assistant professor of Urology at Jefferson Medical College of Thomas Jefferson University, finding the best areas to perform biopsies in the prostate has always been difficult. Standard methods entail simply dividing the prostate into a dozen regions within the gland, almost randomly. Center co-director Ethan Halpern, M.D., who is principal investigator on the four-year, National Cancer Institute-supported trial, has been developing and refining techniques to enhance targeted biopsy of the prostate for more than a decade.

Dr. Trabulsi, Ethan Halpern, M.D., professor of Radiology and Urology at Jefferson Medical College, and their co-workers randomly divided 63 prostate biopsy patients into two groups. One group was given the drug dutasteride, which can reduce the blood flow in benign prostate tissue, while the other half received a placebo. They then compared the results from biopsies targeted by blood flow changes using contrast-enhanced ultrasound to those that were done the standard way. The study involved 979 biopsies.

Weve previously shown that a two-week course of the drug Avodart (dutasteride) before biopsy reduces the benign blood flow, or background noise, Dr. Trabulsi explains, allowing us to see subtle flow changes to target for biopsy. When we did this, we found that targeted biopsies based on the contrast-enhanced ultrasound are much more likely to detect prostate cancer. Thats the exciting part about this.

Dr. Halpern explains that standard procedures fail to diagnose prostate cancer in approximately 30 percent of men with the disease, even though the biopsy protocol may sample 12 to 18 tissue cores from the prostate. In the future, our goal is to perform a limited number of targeted biopsies and leave the rest of the prostate alone, he says. This will provide a safer, more cost-effective approach to diagnosing prostate cancer.

The doctors say that the current study involves a novel ultrasound algorithm called flash replenishment imaging to show fine vascular flow differences. The novelty is using the dutasteride before biopsy, using contrast-enhanced ultrasound and using the latest ultrasound technology to look for blood flow changes associated with prostate cancer.

We are beginning to have patients who were operated on come back in, Dr. Trabulsi notes. If we can show that we reliably hit the areas of cancer based on the ultrasound results and didnt miss any, its a home run.


'/>"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. System Planning Corporation Launches New Asset Tracking and Monitoring System to Meet Pharmaceutical Industry Needs
2. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
3. Transcutaneous cervical esophageal ultrasound can not substitute for 24-h pH monitoring or manometry
4. Axeda Selected for Remote Monitoring and Service of Automation Technologies
5. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
6. Novant Health(R) Selects Cardiocom(R) to Provide Telemonitoring for Presbyterian Hospital Heart Failure Program
7. Cavidi Signs Agreement With the Clinton Foundation HIV/AIDS Initiative to Lower Costs of HIV Monitoring
8. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study
9. Gary Tschautscher of Nonin Medical, Inc. Receives CEO of 2007 for North American Patient Monitoring From Frost & Sullivan
10. EaglePicher Technologies Introduces First Implantable Medical Cell Designed Specifically for Monitoring Applications
11. Bergen County (NJ) Early Adopter of Health Monitoring Systems Mergence(TM) Healthcare Data Integration Engine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... the California Dental Association, today announced it has signed a letter of intent ... Corporation (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 ...
(Date:4/28/2016)... ... 28, 2016 , ... CastCoverz!, America’s #1 trusted brand for ... oldest waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! ... daily, night, weatherproof and waterproof covers for most orthopedic devices, including but not ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the organization’s most successful events, attracting medical professionals from around the globe who ... networking events. , Opening Ceremonies Sunday, April 17 included the introduction of the ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, ... childhood mortality. This is particularly true in underdeveloped parts of Africa where clean sources ... New England’s campus in Tangier, Morocco, will examine this global health issue and consider ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
Breaking Medicine Technology: